---
title: "Drug-wide study associates 31 drug classes with the risk of Parkinsonâ€™s disease"
author: "Julia Romanowska"
institute: "University of Bergen"
date: "2023-11-15"
format:
  revealjs:
    logo: img/UiBmerke_grayscaleV8_transp.png
    theme: solarized
---

```{r}
#' include: false
library(fontawesome)
```

## Take-home message

## How did we come to this conclusion?

::: incremental
- Norwegian Prescription Database
- hypothesis-free screening
- ATC-code level 2, e.g., C09 = agents acting on renin-angiotensin system
:::

---
### 10 drug classes `r fa("arrow-down")` PD-risk, 21 drug classes `r fa("arrow-up")` PD-risk

![](img/pooled_compare_sex_4poster.png){height=650px}

<p style="position: absolute; right: 5px; bottom: 5px; font-size: 12pt;">
significant associations at FDR<0.05
</p>

## Can we trust the results?

::: columns
::: column
PROBLEMS:

- long prodromal phase
- long-term vs. short-term drug usage
:::
::: column
:::
:::

## Can we trust the results?

::: columns
::: column
PROBLEMS:

- long prodromal phase
- long-term vs. short-term drug usage
:::
::: column
SOLUTIONS:

- time-lag analyses
- dose-response analyses
:::
:::

## Drug classes retaining the effect throughout time and doses

## Conclusion

::: callout-tip
## drug classes `r fa("arrow-up")` PD-risk    
help identify patients early
:::

. . .

::: callout-tip
## drug classes `r fa("arrow-down")` PD-risk    
might be repurposed as new treatment
:::
